Codexis, Inc.
A maker of custom-engineered enzymes, Codexis grows proteins in the lab to speed up drug-making and other industrial processes, with uses ranging from pharmaceuticals (including a key ingredient in the cholesterol drug Lipitor) to food and RNA therapies. Born in 2002 as a spin-off from biotech firm Maxygen, the company built its craft on "directed evolution" — mimicking natural selection in a dish to breed better enzymes through its CodeEvolver platform. Its name blends "code" and "exis" (evolution), a nod to the very process that powers it.
Sold 2.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| De Vre RaymondDirector · 1 transaction | -3% | 84.8K | — | — | 2.6K |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: -2.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.